Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanna Axelsson

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Assay and Drug Development Technologies|April 15, 2016
Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule ScreeningKarin Engen, Ulrika Rosenström, Hanna Axelsson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 14, 2017
Prediction of intracellular exposure bridges the gap between target- and cell-based drug discoveryAndré Mateus, Laurie J Gordon, Gareth J Wayne, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 1, 2026
Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancreatic cancer modelsVeronica Barile, Maria Kuzikov, Weiyingqi Cui, et al.
Journal of Biomolecular Screening|May 31, 2012
A homogeneous HTRF assay for the identification of inhibitors of the TWEAK-Fn14 protein interactionTiziana Benicchi, Sara Iozzi, Andreas Svahn, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 17, 2025
Image based subcellular mapping of the protein landscape of SARS-CoV-2 infected cells for target-centric drug repurposingMarianna Tampere, Trang H Le, Elin Asp, et al.
Nature Communications|January 19, 2018
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cellsBrent D G Page, Nicholas C K Valerie, Roni H G Wright, et al.
Nature Communications|November 3, 2019
Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cellsBrent D G Page, Nicholas C K Valerie, Roni H G Wright, et al.
Iscience|February 6, 2024
Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelSi Min Zhang, Cynthia B J Paulin, Huazhang Shu, et al.
EMBO Molecular Medicine|January 18, 2020
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacySean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, et al.
Nature Medicine|January 10, 2017
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignanciesNikolas Herold, Sean G Rudd, Linda Ljungblad, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Assay and Drug Development Technologies|April 15, 2016
Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule ScreeningKarin Engen, Ulrika Rosenström, Hanna Axelsson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 14, 2017
Prediction of intracellular exposure bridges the gap between target- and cell-based drug discoveryAndré Mateus, Laurie J Gordon, Gareth J Wayne, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 1, 2026
Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancreatic cancer modelsVeronica Barile, Maria Kuzikov, Weiyingqi Cui, et al.
Journal of Biomolecular Screening|May 31, 2012
A homogeneous HTRF assay for the identification of inhibitors of the TWEAK-Fn14 protein interactionTiziana Benicchi, Sara Iozzi, Andreas Svahn, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 17, 2025
Image based subcellular mapping of the protein landscape of SARS-CoV-2 infected cells for target-centric drug repurposingMarianna Tampere, Trang H Le, Elin Asp, et al.
Nature Communications|January 19, 2018
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cellsBrent D G Page, Nicholas C K Valerie, Roni H G Wright, et al.
Nature Communications|November 3, 2019
Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cellsBrent D G Page, Nicholas C K Valerie, Roni H G Wright, et al.
Iscience|February 6, 2024
Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelSi Min Zhang, Cynthia B J Paulin, Huazhang Shu, et al.
EMBO Molecular Medicine|January 18, 2020
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacySean G Rudd, Nikolaos Tsesmetzis, Kumar Sanjiv, et al.
Nature Medicine|January 10, 2017
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignanciesNikolas Herold, Sean G Rudd, Linda Ljungblad, et al.
Pageof 3